[1] McCarthy HJ, Bierzynska A, Wherlock M, et al. Simultaneous sequencing of 24 genes associated with steroid-resistant nephritic syndrome[J]. Clin J Am Soc Nephrol, 2013, 8(4): 637-648.
[2] Ren HQ, Chen GF, Zhou X, et al. The clinical efficacy of low-dose tacrolimus combined with tripterygium to treat the steroid-resistant nephrotic syndrome[J]. Open J Nephrol, 2012, 6(2): 97-104.
[3] Jaffer AT, Ahmed WU, Raju DS, et al. Foothold of NPHS2 mutations in primary nephrotic syndrome[J]. J Postgrad Med, 2011, 57(4): 314-320.
[4] Otukesh H, Ghazanfari B, Fereshtehnejad SM, et al. NPHS2 mutations in children with steroid-resistant nephrotic syndrome[J]. Iran J Kidney Dis, 2009, 3(2): 99-102.
[5] Huber TB, Schermer B, Benzing T. Podocin organizes ion channel-lipid supercomplexes: implications for mechanosensation at the slit diaphragm[J]. Nephron Exp Nephrol, 2007, 106(2): 27-31.
[6] Kerti A, Csohany R, Szabo A, et al. NPHS2 p.V290M mutation in late-onset steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2013, 28(5): 751-757.
[7] Santin S, Tazon-Vega B, Silva I, et al. Clinical value of NPHS2 analysis in early-and adult-onset steroid-resistant nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2011, 6(2): 344-354.
[8] Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis[J]. J Am Soc Nephrol, 2001, 12(12): 2742-2746.
[9] Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission[J]. J Am Soc Nephrol, 2005, 16(2): 1061-1068.
[10] Santin S, Tazon-Vega B, Silva I, et al. Clinical value of NPHS2 analysis in early and adult-onset steroid-resistant nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2011, 6(2): 344-354.
[11] 管娜, 丁洁. 儿童肾病综合征激素耐药发生机制研究进展[J]. 临床儿科杂志, 2005, 23(4): 199-201.
[12] Schoeb DS, Chernin G, Heeringa SF, et al. Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS) [J]. Nephrol Dial Transplant, 2010, 25(9): 2970-2976.
[13] 孟大川, 王道静, 余自华, 等. 中国南方汉族人3个家族性激素耐药型肾病综合征家系CD2AP和NPHS1基因突变分析[J]. 实用儿科临床杂志, 2011, 26(5): 329-344.
[14] Santin S, Bullich G, Tazon-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome[J]. Clin J Am Soc Nephrol, 2011, 6(5): 1139-1148.
[15] Yu ZH, Wang DJ, Meng DC, et al. Mutations in NPHS1 in a Chinese child with congenital nephrotic syndrome[J]. Genet Mol Res, 2012, 11(2): 1460-1464.
[16] Machuca E, Benoit G, Nevo F, et al. Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome[J]. J Am Soc Nephrol, 2010, 21(7): 1209-1217.
[17] Abid A, Khaliq S, Shahid S, et al. A spectrum of novel NPHS1 and NPHS2 gene mutations in pediatric nephrotic syndrome patients from Pakistan[J]. Gene, 2012, 502(2): 133-137.
[18] Abid A, Khaliq S, Shahid S, et al. The effects of the WT1 gene on apoptosis and development-related gene expression in porcine kidney fibroblasts and swine testis cells[J]. Mol Reprod Dev, 2013, 80(5): 414-425.
[19] Cho HY, Lee JH, Choi HJ, et al. WT1 and NPHS2 mutations in Korean children with steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2008, 23(1): 63-70.
[20] Li J, Ding J, Zhao D, et al. WT1 gene mutations in Chinese children with early onset nephrotic syndrome[J]. Pediatr Res, 2010, 68(2): 155-158.
[21] Chernin G, Heeringa SF, Gbadegesin R, et al. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2008, 23(9): 1455-1460.
[22] Megremis S, Mitsioni A, Fylaktou I, et al. Broad and unexpected phenotypic expression in Greek children with steroid-resistant nephrotic syndrome due to mutations in the Wilms' tumor 1 (WT1) gene[J]. Eur J Pediatr, 2011, 170(12): 1529-1534.
[23] Anochie IC, Eke FU, Okpere AN. Familial focal segmental glomerulosclerosis (FSGS) in a nigerian family and exclusion of mutations in NPHS2, WT1 and APOL1[J]. West Afr J Med, 2012, 31(4): 273-276.
[24] Xu P, Xu J, Li Z, et al. Expression of TRPC6 in renal cortex and hippocampus of mouse during postnatal development[J]. PLoS One, 2012, 7(6): e38503.
[25] D'Esposito M, Strazzullo M, Cuccurese M, et al. Identification and assignment of the human transient receptor potential channel 6 gene TRPC6 to chromosome 11q21—>q22 [J]. Cytogenet Cell Genet, 1998, 83(1-2): 46-47.
[26] Gigante M, Caridi G, Montemurno E, et al. TRPC6 mutations in children with steroid-resistant nephrotic syndrome and atypical phenotype[J]. Clin J Am Soc Nephrol, 2011, 6(7): 1626-1634.
[27] Heeringa SF, Moller CC, Du J, et al. A novel TRPC6 mutation that causes childhood FSGS[J]. PLoS One, 2009, 4(11): 7771.
[28] Hofstra JM, Lainez S, van Kuijk WH, et al. New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis[J]. Nephrol Dial Transplant, 2013, 28(1): 324-328.
[29] Mir S, Yavascan O, Berdeli A, et al. TRPC6 gene variants in Turkish children with steroid-resistant nephrotic syndrome[J]. Nephrol Dial Transplant, 2012, 27(1): 205-209.
[30] Jafar T, Prasad N, Agarwal V, et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children[J]. Nephrol Dial Transplant, 2011, 26(12): 3968-3974.
[31] Ueda S, Sugimoto K, Yanagida H, et al. Low-density lipoprotein adsorption therapy can restore drug sensitivity for immunosuppressants via inhibitory effects upon MDR-1 gene expression[J]. Ther Apher Dial, 2011, 15(5): 499-503.
[32] Boyer O, Benoit G, Gribouval O, et al. Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome[J]. J Med Genet, 2010, 47(7): 445-452.
[33] Ismaili K, Pawtowski A, Boyer O, et al. Genetic forms of nephrotic syndrome: a single-center experience in Brussels[J]. Pediatr Nephrol, 2009, 24(2): 287-294.
[34] Chen YM, Kikkawa Y, Miner JH. A missense LAMB2 mutation causes congenital nephrotic syndrome by impairing laminin secretion[J]. J Am Soc Nephrol, 2011, 22(5): 849-858.
[35] Mbarek IB, Abroug S, Omezzine A, et al. Novel mutations in steroid-resistant nephrotic syndrome diagnosed in Tunisian children[J]. Pediatr Nephrol, 2011, 26(2): 241-249.
[36] Rohr C, Prestel J, Heidet L, et al. The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes[J]. J Clin Invest, 2002, 109(8): 1073-1082.
[37] Harendza S, Stahl RA, Schneider A. The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism[J]. Cell Mol Biol Lett, 2009, 14(4): 679-691.
[38] Dai S, Wang Z, Pan X, et al. ACTN4 gene mutations and single nucleotide polymorphisms in idiopathic focal segmental glomerulosclerosis[J]. Nephron Clin Pract, 2009, 111(2): c87-c94.
[39] Gigante M, Pontrelli P, Montemurno E, et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS) [J]. Nephrol Dial Transplant, 2009, 24(6): 1858-1864.
[40] Tossidou I, Niedenthal R, Klaus M, et al. CD2AP regulates SUMOylation of CIN85 in podocytes[J]. Mol Cell Biol, 2012, 32(6): 1068-1079.
[41] Benoit G, Machuca E, Nevo F, et al. Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2010, 25(3): 445-451.
[42] Barua M, Brown EJ, Charoonratana VT, et al. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis[J]. Kidney Int, 2013, 83(2): 316-322.
[43] Lee HK, Han KH, Jung YH, et al. Variable renal phenotype in a family with an INF2 mutation[J]. Pediatr Nephrol, 2011, 26(1): 73-76.